

A 35

-- 29. (AMENDED) Use of an antibody which binds to a polypeptide comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26); P32 (SEQ ID NO. 81), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO. 77), human V2 (SEQ ID NO: 78) and human V3 (SEQ ID NO. 83). --

---

A 36

-- 33. (AMENDED) Use of an antibody which binds to a polypeptide comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26 ), P32 (SEQ ID NO: 81), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77), human V2 (SEQ ID NO: 78), human V3 (SEQ ID NO: 83) for the treatment of a disease selected from the group consisting of arthritis, inflammatory dermatosis, inflammatory bowel disease, cancer, kidney fibrosis, inflammatory lung disease, obesity, lupus, cardiovascular disease and diabetes mellitus. --

---

#### REMARKS

Claims 1, 2, 5, 7, 15, 19, 23, 24, 28, 29 and 33 have been amended to correct a recurring change in the sequence listing, notably SEQ ID Nos: 71 and 79 to 81 and 83, respectively.

Similarly, the specification has been amended at pages 4-6, 8, 26, 28, 52, and 99, correcting various references to sequence identification numbers so they will correlate to the sequence listing filed herewith.

No new matter has been added by these amendments. The Examiner is hereby requested to enter these amendments.

CONCLUSION

Applicants request that the above amendments be entered prior to examination on the merits of this application. Early and favorable examination is hereby requested.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: Mary Ann Dillahunty  
Mary Ann Dillahunty  
Registration No. 34,576

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(650) 622-2300

Date: January 17, 2002

**Attachment to Preliminary Amendment**  
**Dated: November 19, 2001**  
**Marked up Claims 1, 2, 5, 7, 15, 19, 23, 24, 28, 29 and 33**

**In the Claims:**

Please amend Claims 1, 2, 5, 7, 15, 19, 23, 24, 28, 29, and 33 by replacing them with the following:

-- 1. (AMENDED) Polypeptide comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26), P32 (SEQ ID NO: [71] 81), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77) and human V2 (SEQ ID NO: 78). --

-- 2. (AMENDED) A pharmaceutical composition for the treatment of an inflammatory neurological disorder comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26), P32 (SEQ ID NO: [71] 81), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77), and human V2 (SEQ ID NO: 78). --

-- 5. (AMENDED) A pharmaceutical composition for the treatment of diabetes mellitus comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26), P32 (SEQ ID NO: [71] 81), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77), human V2 (SEQ ID NO: 78). --

-- 7. (AMENDED) An antibody which binds to a polypeptide comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26), P32 (SEQ ID NO: [71] 81), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77), human V2 (SEQ ID NO: 78), murine V3 (SEQ ID NO: [79] 83), human V3 (SEQ ID NO: 80). --

-- 15. (AMENDED) A method for treating an inflammatory neurological disorder comprising the step of administering to a patient a compound selected from the group consisting of (a) a polypeptide comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26), P32 (SEQ ID NO: [71] 81), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77), human V2 (SEQ ID NO: 78), human V3 (SEQ ID NO: [79] 83) and (b) an antibody to the polypeptide of (a). --

-- 19. (AMENDED) A method for treating a disease selected from the group consisting of arthritis, inflammatory dermatosis, inflammatory bowel disease, cancer, kidney fibrosis, inflammatory lung disease, obesity, lupus, cardiovascular disease and diabetes mellitus, the method comprising the step of administering to a patient a compound selected from the group consisting of (a) a polypeptide comprising an amino acid sequence selected from the group consisting P16 (SEQ ID NO: 26), P32 (SEQ ID NO: [71] 81), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77), human V2 (SEQ ID NO: 78), human V3 (SEQ ID NO: [79] 83) and (b) an antibody to the polypeptide of (a). --

-- 23. (AMENDED) A method for treating wounds comprising the step of administering to a patient a compound selected from the group consisting of (a) a polypeptide comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26), P32 (SEQ ID NO: [71] 81), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77), human V2 (SEQ ID NO: 78), human V3 (SEQ ID NO: [79] 83) and (b) an antibody to the polypeptide of (a). --

-- 24. (AMENDED) Use of polypeptide comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26) P32 (SEQ ID NO: [71] 81), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77), human V2 (SEQ ID NO: 78), human V3 (SEQ ID NO: [79] 83) for the treatment of an inflammatory neurological disorder. --

-- 28. (AMENDED) Use of a polypeptide comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26), P32 (SEQ ID NO: [71] 81), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77), human V2 (SEQ ID NO: 78), human V3 (SEQ ID NO: [79] 83) for the treatment of a disease selected from the group consisting of arthritis, inflammatory dermatosis, inflammatory bowel disease, cancer, kidney fibrosis, inflammatory lung disease, obesity, lupus, cardiovascular disease and diabetes mellitus. --

-- 29. (AMENDED) Use of an antibody which binds to a polypeptide comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26); P32 (SEQ ID NO. [71] 81), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO. 77), human V2 (SEQ ID NO: 78) and human V3 (SEQ ID NO. [79] 83). --

-- 33. (AMENDED) Use of an antibody which binds to a polypeptide comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26 ), P32 (SEQ ID NO: [71] 81), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77), human V2 (SEQ ID NO: 78), human V3 (SEQ ID NO: [79] 83) for the treatment of a disease selected from the group consisting of arthritis, inflammatory dermatosis, inflammatory bowel disease, cancer, kidney fibrosis, inflammatory lung disease, obesity, lupus, cardiovascular disease and diabetes mellitus. --